We invite you to participate in a new SOLACI virtual event open to the entire community. It will be carried out with the support of Boston Scientific and it will have the participation of prestigious hemodynamicists from all over Latin America. The event will take place on next Saturday, May 1 at 11.00 a.m. (Argentine time;…
IVUS vs OCT to Guide PCI: Which Should We Choose?
Controlling stent expansion with optical coherence tomography (OCT) based on an external elastic membrane–based protocol for stent sizing resulted non-inferior to the control group which used intravascular ultrasound (IVUS) and superior the angiography only group. Based on these study outcomes and the prior outcomes, we should use IVUS imaging if available. There are no specific algorithms…
27/04 | SOLACI / BIOTRONIK Webinar
We invite you to participate in a new SOLACI virtual event open to the entire community. It will be carried out with the support of BIOTRONIK and it will have the participation of prestigious hemodynamicists from all over Latin America. The event will take place on next Tuesday, April 27 at 7:30 p.m. (Argentine time;…
The Future of Prevention? Stenting Vulnerable Fractional FFR Negative Lesions
For many patients, the first symptom of heart disease is acute MI, or even sudden death. Changes in lifestyle and optimal medical treatment (OMT) are vital to the prevention of serious events, but we cannot help wondering whether preventive stenting might do it. Intravascular ultrasound (IVUS), optical coherence tomography (OCT), NIRS near-infrared spectroscopy (NIRS) and computed…
Post MI Betablockers for Good?
Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration. This study looked into the cardio protection effect of betablockers (BB) after long term follow up in stable patients with no cardiac failure and a history…
Impact of FFR After Stenting: Useful or Mere Fun Fact?
Suboptimal fractional flow reserve (FFR) results after stenting only have a moderate impact on clinical hard points but might predict a much higher risk of reintervention. FFR has shown a huge impact on the decision-making process when it comes to revascularizing (or not) a lesion. Its impact after angioplasty has not been fully studied, particularly…
Short Therapy and Monotherapy, Plenty of Evidence
A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after second generation drug eluting stent (DES) implantation is safer and as effective as the traditional scheme. The idea is clear, but why hasn’t aspirin monotherapy been tested as follow up? Is aspirin old fashioned? Are there physiopathological reasons…
Lower Mortality with Rechanneling vs. Medical Therapy
We had to wait for it, but we have finally seen a benefit in hard endpoints—such as mortality—derived from rechanneling. Patients with chronic total occlusion (CTO) in whom rechanneling was used as initial strategy showed higher survival rated compared with those receiving medical therapy. As initial treatment strategy, rechanneling a CTO did not show any…
Biodegradable Polymer Myth Also Debunked for ACSs
During TCT 2020 a preview of the results of the comparison of drug-eluting stents (DES) with biodegradable-polymer vs. durable-polymer in patients with acute coronary syndrome (ACS) was presented. The fine print and the final paper for HOST-REDUCE-POLYTECH-ACS are now published, and they lower the expectations set on biodegradable polymers. In patients with ACS undergoing angioplasty, biodegradable-polymer…
Should Total Occlusion Influence on Revascularization Strategy?
Success or failure of total occlusion (TO) revascularization does not affect mortality at 10 years, and this does not depend on revascularization strategy (PCI vs surgery) or location. The long-term clinical benefit of recanalization and PCI or TO artery bypass graft remains nuclear. This is a sub-study of the SYNTAXES (Synergy Between PCI With Taxus…
MATRIX: Impact of Crossover from Radial Access to Femoral Access
The new MATRIX trial, recently published in JACC Interv., shows that an access-site crossover from radial to femoral access in patients with acute coronary syndrome cancels out the benefit provided by radial access as regards bleeding. However, there are no signs of comparative damage between successfully conducted radial or femoral access as a first attempt. …